Vitamin D Supplementation in HIV

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate safety and efficacy of vitamin D supplementation in children, adolescents and young adults with Human Immunodeficiency Virus and acquired immunodeficiency syndrome (HIV/AIDS). The study is a 12-month randomized, double blind, placebo-controlled study of vitamin D3 (vit D) supplementation using 7000IU/day based on evidence from the Vit D Dose Finding Study-IRB 09-007332.

Clinical Trial Description

Optimal vitamin D (vit D) concentration and metabolism are essential for normal immune function, growth, muscle, bone, and inflammatory status in children, adolescents and adults with HIV/AIDS. The impact of vit D supplementation will be evaluated for safety and efficacy using clinically important outcomes, and this will overcome the critical barrier for use of vit D supplementation in research and clinical care. Inexpensive and easy to administer, vit D supplementation may prove to be an effective and feasible treatment for symptoms and prevention of side effects for people of all ages living with HIV/AIDS in the US and around the world.

The study is a 12-month randomized, double blind, placebo-controlled study of vitamin D3 (vit D) supplementation using 7000IU/day based on evidence from the Vit D Dose Finding Study-IRB 09-007332 in 58 subjects with both Perinatally Acquired (PA) and Behaviorally Acquired (BA) HIV/AIDS to assess the long-term safety in terms of serum calcium and 25OHD concentrations, and efficacy in terms of the effect of vit D supplementation on 25OHD, cathelicidin, growth (pre- and peripubertal participants), body composition, bone, muscle, immune and inflammatory status and HIV/AIDS disease severity and progression.

Primary Hypotheses:

H1: Vit D supplementation is safe and does not result in an increased incidence of elevated serum calcium (above age-specific range) associated with elevated serum 25OHD (>160 ng/mL) in treated subjects compared with the subjects receiving placebo.

H2: Vit D supplementation is significantly associated with both increased 25D and cathelicidin in treated subjects compared with subjects receiving placebo. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01475890
Study type	Interventional
Source	Children's Hospital of Philadelphia
Contact
Status	Completed
Phase	Phase 2/Phase 3
Start date	July 2011
Completion date	February 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00787696` - Healthy Teen Girls: HIV Risk Reduction	Phase 1/Phase 2
Completed	`NCT03403569` - Safety and Efficacy of Triptolide Wilfordii in New Onset HIV-1 Infection	Phase 3
Completed	`NCT02433743` - Impact of RUTF on Body Composition, Anemia and Zinc Status of PLWHA	N/A
Recruiting	`NCT02753049` - Adherence Connection for Counseling, Education, and Support	N/A
Completed	`NCT01360762` - Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients With Pentamidine: a Cohort Study	Phase 3
Recruiting	`NCT03147859` - Vedolizumab Treatment in Antiretroviral Drug Treated Chronic HIV Infection	Phase 2
Recruiting	`NCT04297488` - Probiotic Supplementation for Those Immune Non-responders With HIV-1 Infection	N/A
Completed	`NCT01827540` - Study of Dolutegravir (DTG) on PK of Cenicriviroc (CVC), and CVC on PK of DTG & on a Single Dose of Midazolam	Phase 1
Recruiting	`NCT05947539` - Improving HIV Care Engagement Among Ugandan Adolescent Girls and Young Women: The Kisoboka Mukwano Intervention	N/A
Withdrawn	`NCT01442428` - Paradoxical Tuberculosis Immune Reconstitution Inflammatory Syndrome (TB-IRIS) Treatment Trial	Phase 2/Phase 3
Completed	`NCT02496793` - Community-Based Peer Facilitator Intervention (Zimbabwe)	N/A
Completed	`NCT03069235` - Promoting Exclusive Breastfeeding Among HIV Infected Women in a PMTCT Program	N/A
Completed	`NCT03794648` - The Effectiveness of a Mobile Interactive Supervised Therapy (MIST) Intervention for Improving Adherence to HIV Medication	N/A
Withdrawn	`NCT04183738` - Inflammation and Co-Infections in D²EFT	Phase 4
Enrolling by invitation	`NCT03919695` - Development of an Intervention to Reduce Heavy Drinking and Improve HIV Care Engagement Among Fisherfolk in Uganda	N/A
Recruiting	`NCT04215926` - NAFLD in HIV-infected Patients
Completed	`NCT01406626` - Effectiveness of Peer Navigation to Link Released HIV+ Jail Inmates to HIV Care	N/A
Completed	`NCT04371835` - COHIVE: Coronavirus (COVID-19) Outcomes in HIV Evaluation in Resource Limited Settings
Completed	`NCT01140633` - Novel Measures and Theory of Pediatric Antiretroviral Therapy Adherence in Uganda	N/A
Enrolling by invitation	`NCT04373551` - WeExPAnd: PrEP Demonstration Project Among Women at Risk for HIV Infection - Preexposure Prophylaxis (PrEP)	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.